Semaglutide + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatobiliary Disorders
Conditions
Hepatobiliary Disorders, Non-alcoholic Steatohepatitis
Trial Timeline
Nov 30, 2016 → Mar 19, 2020
NCT ID
NCT02970942About Semaglutide + Placebo
Semaglutide + Placebo is a phase 2 stage product being developed by Novo Nordisk for Hepatobiliary Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT02970942. Target conditions include Hepatobiliary Disorders, Non-alcoholic Steatohepatitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06041217 | Phase 3 | Completed |
| NCT05726227 | Phase 3 | Active |
| NCT05891496 | Phase 3 | Completed |
| NCT05486065 | Phase 2 | Completed |
| NCT04889183 | Phase 3 | Completed |
| NCT04979130 | Approved | Completed |
| NCT04822181 | Phase 3 | Active |
| NCT03842202 | Phase 1 | Completed |
| NCT03548987 | Phase 3 | Completed |
| NCT03357380 | Phase 1 | Completed |
| NCT03086330 | Phase 3 | Completed |
| NCT02692716 | Phase 3 | Completed |
| NCT02970942 | Phase 2 | Completed |
| NCT02906930 | Phase 3 | Completed |
| NCT02827708 | Phase 3 | Completed |
| NCT02773381 | Phase 1 | Completed |
| NCT02557620 | Phase 1 | Completed |
| NCT02305381 | Phase 3 | Completed |
| NCT02212067 | Phase 1 | Completed |
| NCT02161588 | Phase 1 | Completed |
Competing Products
4 competing products in Hepatobiliary Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Trastuzumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| Semaglutide + Placebo | Novo Nordisk | Phase 1 | 32 |
| Phosphatidylcholine | Sanofi | Phase 3 | 76 |
| Zimberelimab + Domvanalimab | Arcus Biosciences | Phase 2 | 47 |